Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies (Q37998724)

26 August 2017

Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies (English)

1 reference

26 August 2017

1 reference

Carlo Gabriele Tocchetti

2

object named as

Carlo G Tocchetti

1 reference

26 August 2017

Harry J. G. M. Crijns

5

object named as

Harry J Crijns

1 reference

26 August 2017

Yanti Octavia

1

1 reference

26 August 2017

Kathleen L Gabrielson

3

1 reference

26 August 2017

Stefan Janssens

4

1 reference

26 August 2017

An L Moens

6

1 reference

26 August 2017

language of work or name

1 reference

21 March 2012

1 reference

Journal of Molecular and Cellular Cardiology

26 August 2017

1 reference

26 August 2017

52

1 reference

26 August 2017

6

1 reference

26 August 2017

1213-1225

1 reference

Cardiotoxicity of doxorubicin and other anthracycline derivatives

26 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Lack of clinically significant cardiac dysfunction during intermediate dobutamine doses in long-term childhood cancer survivors exposed to anthracyclines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Cardiac function in Wilms' tumor survivors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Increased risk of cardiac dysfunction after anthracyclines in girls

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Doxorubicin cardiotoxicity in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Anthracycline-induced cardiotoxicity in children with malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Cardiac abnormalities 15 years and more after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut Gustave Roussy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Doxorubicin-induced cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Effects by doxorubicin on the myocardium are mediated by oxygen free radicals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Molecular basis of anthracycline-induced cardiotoxicity and its prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Evidence of a complex between adriamycin derivatives and cardiolipin: possible role in cardiotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

The biosynthesis and functional role of cardiolipin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Inhibition of mitochondrial carnitine palmitoyltransferases by adriamycin and adriamycin analogues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Energy metabolism in heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

The protective roles of nitric oxide and superoxide dismutase in adriamycin-induced cardiotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Structural and functional impairment of mitochondria in adriamycin-induced cardiomyopathy in mice: suppression of cytochrome c oxidase II gene expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Metabolic remodeling associated with subchronic doxorubicin cardiomyopathy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Heme oxygenase-1 regulates cardiac mitochondrial biogenesis via Nrf2-mediated transcriptional control of nuclear respiratory factor-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Protective effect of calceolarioside on adriamycin-induced cardiomyocyte toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Attenuation of doxorubicin-induced contractile and mitochondrial dysfunction in mouse heart by cellular glutathione peroxidase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Doxorubicin-induced apoptosis is associated with increased transcription of endothelial nitric-oxide synthase. Effect of antiapoptotic antioxidants and calcium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Adverse ventricular remodeling and exacerbated NOS uncoupling from pressure-overload in mice lacking the beta3-adrenoreceptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Disruption of nitric oxide synthase 3 protects against the cardiac injury, dysfunction, and mortality induced by doxorubicin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Rapid-onset endothelial dysfunction with adriamycin: evidence for a dysfunctional nitric oxide synthase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Human neuronal nitric oxide synthase can catalyze one-electron reduction of adriamycin: role of flavin domain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Nitric oxide synthase expressions in ADR-induced cardiomyopathy in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Gp91phox-containing NAD(P)H oxidase increases superoxide formation by doxorubicin and NADPH.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

NADPH oxidases participate to doxorubicin-induced cardiac myocyte apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Solution chemistry studies of adriamycin-iron complexes present in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Molecular pharmacology of the interaction of anthracyclines with iron

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

The secondary alcohol metabolite of doxorubicin irreversibly inactivates aconitase/iron regulatory protein-1 in cytosolic fractions from human myocardium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Hfe deficiency increases susceptibility to cardiotoxicity and exacerbates changes in iron metabolism induced by doxorubicin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Potentiation of Doxorubicin cardiotoxicity by iron loading in a rodent model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Transfusion iron overload in adults with acute leukemia: manifestations and therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Role of oxidative stress in cardiovascular diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Activity of d,l-alpha-tocopherol (vitamin E) against cardiotoxicity induced by doxorubicin and doxorubicin with cyclophosphamide in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Reactive oxygen species regulate FLICE inhibitory protein (FLIP) and susceptibility to Fas-mediated apoptosis in cardiac myocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Role of heat shock factor-1 activation in the doxorubicin-induced heart failure in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Hsp10 and Hsp60 modulate Bcl-2 family and mitochondria apoptosis signaling induced by doxorubicin in cardiac muscle cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Heat shock protein 20 interacting with phosphorylated Akt reduces doxorubicin-triggered oxidative stress and cardiotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Extracellular heat shock protein 60, cardiac myocytes, and apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Extracellular release of the atheroprotective heat shock protein 27 is mediated by estrogen and competitively inhibits acLDL binding to scavenger receptor-A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Modulation of doxorubicin-induced cardiac dysfunction in toll-like receptor-2-knockout mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Toll-like receptor-4 deficiency attenuates doxorubicin-induced cardiomyopathy in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Activation of nuclear factor-kappaB during doxorubicin-induced apoptosis in endothelial cells and myocytes is pro-apoptotic: the role of hydrogen peroxide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Doxorubicin induces apoptosis by activation of caspase-3 in cultured cardiomyocytes in vitro and rat cardiac ventricles in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Induction of caspase-independent apoptosis in H9c2 cardiomyocytes by adriamycin treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Caspase-dependent and -independent suppression of apoptosis by monoHER in Doxorubicin treated cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Nitric oxide inhibits myocardial apoptosis by preventing caspase-3 activity via S-nitrosylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

The volume-sensitive chloride channel inhibitors prevent both contractile dysfunction and apoptosis induced by doxorubicin through PI3kinase, Akt and Erk 1/2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Doxorubicin activates nuclear factor of activated T-lymphocytes and Fas ligand transcription: role of mitochondrial reactive oxygen species and calcium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Mechanism of doxorubicin-induced inhibition of sarcoplasmic reticulum Ca(2+)-ATPase gene transcription

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Patterns of interaction between anthraquinone drugs and the calcium-release channel from cardiac sarcoplasmic reticulum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Doxorubicin directly binds to the cardiac-type ryanodine receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

The cardiotoxic antibiotic doxorubicin inhibits the Na+ /Ca2+ exchange of dog heart sarcolemmal vesicles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

L-type cardiac calcium channels in doxorubicin cardiomyopathy in rats morphological, biochemical, and functional correlations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Hydrogen peroxide stimulates the Ca2+ release channel from skeletal muscle sarcoplasmic reticulum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Doxorubicin treatment in vivo activates caspase-12 mediated cardiac apoptosis in both male and female rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Dose-dependent increase in sensitivity to calcium-induced mitochondrial dysfunction and cardiomyocyte cell injury by doxorubicin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

A digitized-fluorescence-imaging study of mitochondrial Ca2+ increase by doxorubicin in cardiac myocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Heat shock protein 90 and ErbB2 in the cardiac response to doxorubicin injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Heat shock protein 90 stabilization of ErbB2 expression is disrupted by ATP depletion in myocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

erbB2 is required for G protein-coupled receptor signaling in the heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Effect of cardiac dysfunction on treatment outcomes in women receiving trastuzumab for HER2-overexpressing metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Acute toxicity of doxorubicin on isolated perfused heart: response of kinases regulating energy supply

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Nuclear magnetic resonance study of high-energy phosphate stores in models of adriamycin cardiotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Effects of the anti-cancer drug adriamycin on the energy metabolism of rat heart as measured by in vivo 31P-NMR and implications for adriamycin-induced cardiotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

The impairment of essential fatty acid metabolism as a key factor in doxorubicin-induced damage in cultured rat cardiomyocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

The relationship between cardiac function and metabolism in acute adriamycin-treated perfused rat hearts studied by 31P and 13C NMR spectroscopy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Free radical inactivation of rabbit muscle creatinine kinase: catalysis by physiological and hydrolyzed ICRF-187 (ICRF-198) iron chelates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Intracellular distribution of peroxynitrite during doxorubicin cardiomyopathy: evidence for selective impairment of myofibrillar creatine kinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

A novel pharmacological action of ET-1 to prevent the cytotoxicity of doxorubicin in cardiomyocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Coordinated upregulation of the cardiac endothelin system in a rat model of heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Functional effects of endothelin and regulation of endothelin receptors in isolated human nonfailing and failing myocardium.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Increased plasma endothelin-1 and cardiac nitric oxide during doxorubicin-induced cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Endothelin-mediated cardiorenal hemodynamic and neuroendocrine effects are attenuated by nitroglycerin in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

The endothelin receptor blocker bosentan inhibits doxorubicin-induced cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Conditional cardiac overexpression of endothelin-1 induces inflammation and dilated cardiomyopathy in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Alteration of matrix metalloproteinases in selective left ventricular adriamycin-induced cardiomyopathy in the pig.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Matrix metalloproteinase-2 and -9 are induced differently by doxorubicin in H9c2 cells: The role of MAP kinases and NAD(P)H oxidase.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Early effects of doxorubicin in perfused heart: transcriptional profiling reveals inhibition of cellular stress response genes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Diclofenac sodium, a nonselective nonsteroidal anti-inflammatory drug aggravates doxorubicin-induced cardiomyopathy in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Acute doxorubicin cardiotoxicity is associated with miR-146a-induced inhibition of the neuregulin-ErbB pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

L-carnitine prevents doxorubicin-induced apoptosis of cardiac myocytes: role of inhibition of ceramide generation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Volume-sensitive chloride channels (ICl,vol) mediate doxorubicin-induced apoptosis through apoptotic volume decrease in cardiomyocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

CB1 cannabinoid receptors promote oxidative stress and cell death in murine models of doxorubicin-induced cardiomyopathy and in human cardiomyocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Anandamide preserves cardiac function and geometry in an acute doxorubicin cardiotoxicity rat model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Toxic cardiomyopathy due to doxorubicin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Subacute anthracycline cardiotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Reversibility of severe left ventricular dysfunction due to doxorubicin cardiotoxicity. Report of three cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Early detection of anthracycline induced cardiotoxicity in asymptomatic patients with normal left ventricular systolic function: autonomic versus echocardiographic variables

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Monitoring chemotherapy-induced cardiotoxicity: role of cardiac nuclear imaging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Early detection of doxorubicin cardiomyopathy using two-dimensional strain echocardiography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Dobutamine stress echocardiography: a sensitive indicator of diminished myocardial function in asymptomatic doxorubicin-treated long-term survivors of childhood cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Elevated B-type natriuretic peptide levels after anthracycline administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Pharmacokinetics of doxorubicin in man: dose and schedule dependence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

An effective low-dose adriamycin regimen as secondary chemotherapy for metastatic breast cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Metabolism of the one-ring open metabolites of the cardioprotective drug dexrazoxane to its active metal-chelating form in the rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

New synthetic flavonoids as potent protectors against doxorubicin-induced cardiotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Monohydroxyethylrutoside as protector against chronic doxorubicin-induced cardiotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

The effect of monohydroxyethylrutoside on doxorubicin-induced cardiotoxicity in patients treated for metastatic cancer in a phase II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Protective effects of carvedilol against anthracycline-induced cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36-month follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Treatment with angiotensin-converting-enzyme inhibitor for epirubicin-induced dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Cardioprotective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

ACE inhibition and protection from doxorubicin-induced cardiotoxicity in the rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Angiotensin-converting enzyme inhibition and angiotensin AT(1)-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Erythropoietin pretreatment protects against acute chemotherapy toxicity in isolated rat hearts.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Influence of the phosphodiesterase-5 inhibitor, sildenafil, on sensitivity to chemotherapy in breast tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Resveratrol treatment protects against doxorubicin-induced cardiotoxicity by alleviating oxidative damage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Usefulness of cardiac resynchronization therapy in the management of Doxorubicin-induced cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Pediatric heart transplantation for anthracycline cardiomyopathy: cancer recurrence is rare

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2012.03.006

10.1016/J.YJMCC.2012.03.006

7 January 2021

Identifiers

DOI

1 reference

26 August 2017

1 reference